Market Research Logo

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

Summary

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 32 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.

The latest report Telomerase Reverse Transcriptase - Pipeline Review, H1 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 2, 1, 10 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health, Metabolic Disorders and Respiratory which include indications Alzheimer's Disease, Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Solid Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Lung Adenocarcinoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing, Renal Cell Carcinoma, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
Argos Therapeutics Inc
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
Inovio Pharmaceuticals Inc
Invectys SA
Johnson & Johnson
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
AGS-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dendritic Cell Therapy + TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-2300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Alzheimer's Disease and Pulmonay Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KML-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ribovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rocapuldencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCPVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
Featured News & Press Releases
Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres
Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2
Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine
Dec 12, 2017: Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
Nov 20, 2017: Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
Nov 11, 2017: Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
Nov 10, 2017: Inovio Pharmaceuticals Presents data on INO-1400 at Society for Immunotherapy of Cancer Conference
Nov 06, 2017: Argos Announces Receipt of Milestone Payment from Lummy
Nov 01, 2017: Janssen to Present Abstracts on Imetelstat at ASH 2017
Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor
Oct 31, 2017: Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Argos Therapeutics Inc, H1 2018
Pipeline by Asterias Biotherapeutics Inc, H1 2018
Pipeline by e-Therapeutics Plc, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by Invectys SA, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Komipharm International Co Ltd, H1 2018
Pipeline by Mediolanum farmaceutici SpA, H1 2018
Pipeline by Telocyte LLC, H1 2018
Pipeline by TILT Biotherapeutics Ltd, H1 2018
Pipeline by Ultimovacs AS, H1 2018
Pipeline by Vaxon Biotech, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd..1), H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report